Results for "consumer data right"
401-410 of 562 results for 'consumer data right'
No relief from pain for Maxigesic claims
AFT Pharmaceuticals (AU) Pty Limited v Reckitt Benckiser (Australia) Pty Limited [2020] FCAFC 45 serves as an important reminder of the risks of comparative advertising and the need for adequate scientific foundations to support representations claiming to be based in science. ...
Winning a US copyright suit not as easy as you thought – lessons from Blackbeard, Led Zeppelin and Katy Perry
In the world of music, proving copyright infringement just got harder – which is only one major issue arising from recent US copyright litigation. We give you an update on these significant case ...
Federal Court decides second round of fencing (patent) duel
This Insight examines the consequences of a patent dispute concerning a patent for a 'fence plinth'. This dispute highlights some of the key elements of any patent dispute such as how meaning of ordinary terms in the patent must be understood in the context of the whole patent specification. ...
Board skills in focus: emerging trends in disclosure and ASX governance developments
The new Advisory Group on Corporate Governance (the AGCG) is currently considering proposed revisions to the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations (the ...
Access allowed: exposure draft released for latest copyright reform bill
On 21 December 2021, the Australian Government released an Exposure Draft of the Copyright Amendment (Access Reform) Bill and an accompanying Discussion Paper. This represents the final package of the government's copyright reforms in response to the 2016 Intellectual Property Arrangements inquiry b ...
Final report on review of Australia’s patent system
The Federal Government has released the final report on the review of the accessibility of patents for small and medium sized enterprises (SMEs), which follows the phasing-out of the innovation patent system in Australia. ...
Swiss claims and skinny labels: Full Federal Court considers infringement
An enlarged bench of the Full Federal Court has considered the principles applying to infringement of Swiss-style claims, with the decision potentially limiting the application of Swiss-style claims in the context of so-called second medical use patents, where the allegedly infringing products are ʽskinny-labelled’. ...
Down-scheduling CBD and growing Australia's cannabis industry
The Therapeutics Goods Administration is proposing amendments to the Poisons Standard to permit pharmacists to sell low-dose cannabidiol (CBD) products without a prescription. Businesses intending to import, manufacture and supply cannabis products in the Australian market should monitor these developments closely. ...
The post-election anti-bribery landscape
In this Insight, we consider how federal anti-bribery laws may evolve under the Albanese government, and comment on its possible use of sanctions. ...
Responding to COVID-19: your questions answered
In light of the global outbreak of coronavirus (COVID-19), many businesses are confronted with questions about the legal and regulatory implications. Here we address the most pressing questions being asked across the business landscape. ...